

<p style="text-align: center;"><b>York/Adams Drug and Alcohol Commission Treatment Policy and Procedure Manual</b></p>	<p><i>Number: C-7</i></p> <p><i>Policy: Opioid Medication Assisted Treatment (MAT)</i></p>
<p><i>Creation Date : 1/10/22</i> <i>Effective Date: 1/10/22</i></p>	<p style="text-align: right;"><i>Page: 1 of 2</i></p>

***I. Purpose:***

To ensure that individuals with a substance use disorder (SUD), for which there is an opioid medication treatment, receive education and access to those treatments based upon their individual needs and preferences.

***II. Policy:***

A combination of medication and behavioral therapies is effective in the treatment of SUD and can help some people to sustain recovery. Medication Assisted Treatment or (MAT) is the use of medications in combination with counseling and behavioral therapies for the treatment of substance use disorders. This coordination of care between therapeutic and pharmaceutical interventions is critical. As such, a fully accessible coordination of all forms of Opioid MAT across York and York and Adams County, which shall include education, induction and/or maintenance of MAT at all SCA contracted levels of care shall occur.

***A. Education:***

All appropriate individuals will be thoroughly educated on the benefits and risks of opioid MAT, and the risk of overdose for abstinence-based treatment without any medication for opioid use disorders. To ensure this education occurs, the associated form, “Opioid Medication Assisted Treatment Education and Access Form” shall be utilized. This form shall record that the individual was provided with education on these benefits and risks as well as education on the various forms of opioid MAT in addition to education regarding naloxone and how to obtain it. The client’s name in addition to the staff who provided the education and date shall be recorded on this form.

***B. Access and Referral to MAT:***

All forms of Opioid MAT shall be accessible to individuals eligible for SCA funding. All treatment including medication must be individualized. MAT shall be voluntarily accepted. Limitations may not be placed on these services nor shall the length of these services be restricted. All forms of opioid MAT must be made available at all levels of care even if the substance use disorder treatment provider is not the prescriber of the medication. Treatment and non-treatment providers may not exclude individuals on MAT from being admitted into services. Providers must admit and provide services to individuals who use opioid MAT for a substance use disorder. In the event that the provider is unable to meet the individuals opioid MAT access needs directly, they must work through an appropriate referral to a prescriber. In situations where the substance use disorder treatment provider and the opioid MAT prescriber are not the same the provider must ensure coordination of care with proper consent. In the event the provider capacity is insufficient to treat individuals who are in need of or are using opioid

MAT, the provider shall make the SCA aware. In the event the individual does not meet criteria for SCA funding the individual must be provided information and referral regarding access to opioid MAT to through other resources, such as medical assistance or third-party insurance. Further, in the event that MAT coordination services are available in the community such as funded by the SCA or other, the provider shall work appropriately with these services to ensure MAT access and support.

C. Funding:

DDAP funds may only be used to pay for MAT using FDA-approved medications. DDAP identified state or federal funds may not be permitted for use outside of FDA- approved medications in the treatment of substance use disorder. Contracted providers that restrict admission based upon medication use may not receive these funds to treat any individual or provide any type of prevention, intervention, treatment, or treatment related service. The Substance Abuse and Mental Health Services Administration's (SAMHSA) website: <https://www.samhsa.gov/medication-assisted-treatment> contains a list of FDA-approved medications.

The SCA may at its discretion and on an individualized basis use non-DDAP or federal funds or other restricted funds to pay for non FDA-approved medications.

Funding for opioid MAT other than methadone, is restricted for individuals who have either:

- 1.) Had a level of care assessment and are in the process of placement into licensed substance use disorder treatment;
- 2.) Enrolled in licensed substance use disorder treatment; or
- 3.) Successfully completed licensed substance use disorder treatment

Invoicing for opioid MAT shall the reimbursed at the physician/pharmacy cost. These services may be provided in-house by the treatment agency or shall be coordinated and subcontracted the billing agency. The provider shall be responsible for invoicing the SCA for all physician/pharmacy costs. Invoices that are not filtered through contracted treatment agencies shall not be considered.

In order to bill for these services, please adhere to the most current SCA Fee for Service Invoice/Report for opioid medication assisted treatment. Please note that the SCA must receive the physician and pharmacy bills with your SCA invoice in order for it to be processed. The prescribing physician as well as the dosage amount and dates must be submitted on this invoice.

Approved By:



YADAC Administrator

1/10/2022

Date